For large-scale production, human iPSC-derived anti-CD19 CAR-M cells expanded in bioreactors exhibit specific phagocytic capacity against CD19+ leukemia cells, and single-cell sequencing confirms their ability to recruit adaptive immune cells through chemokine secretion (310). Here, CD19 is linked to leukemia.